NASDAQ:ISPC iSpecimen (ISPC) Stock Price, News & Analysis $3.45 -0.12 (-3.36%) Closing price 05/22/2026 04:00 PM EasternExtended Trading$3.69 +0.24 (+6.96%) As of 05/22/2026 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock About iSpecimen Stock (NASDAQ:ISPC) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get iSpecimen alerts:Sign Up Key Stats Today's Range$3.20▼$3.5950-Day Range$3.40▼$11.3852-Week Range$3.20▼$127.20Volume154,626 shsAverage Volume823,717 shsMarket Capitalization$4.97 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingSell Company Overview iSpecimen, Inc. (NASDAQ:ISPC) operates an online life sciences marketplace designed to connect researchers with human biological specimens and associated clinical data. The company’s platform streamlines the sourcing of biospecimens—such as plasma, serum, fresh and frozen tissue, saliva, urine and peripheral blood mononuclear cells (PBMCs)—by matching demand from pharmaceutical, biotechnology, diagnostic and academic organizations with supply from a wide network of clinical sites and biobanks. Through its on-demand procurement model, iSpecimen provides customized specimen collection and fulfillment services that help accelerate research timelines and improve data quality. Clients can specify criteria such as disease state, treatment history, demographics and sample processing requirements, while the company manages regulatory compliance, informed consent documentation and quality assurances in accordance with HIPAA, FDA and international guidelines. Founded in 2015 and headquartered in Boston, Massachusetts, iSpecimen has gradually expanded its footprint to include partnerships with specimen providers across North America and select global markets. The company leverages its proprietary technology and centralized logistics to reduce lead times and deliver specimens and data under controlled chain-of-custody conditions. Over time, iSpecimen has supported thousands of research studies spanning oncology, neurology, immunology, cardiovascular disease and infectious disease. Under the leadership of founder and CEO Eddie Clarke, iSpecimen continues to evolve its platform by adding new specimen types, enhancing data annotation tools and forging collaborations with contract research organizations and diagnostic developers. The company’s marketplace model aims to address critical bottlenecks in translational and clinical research by making high-quality human biospecimens more accessible to investigators worldwide.AI Generated. May Contain Errors. Read More iSpecimen Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks7th Percentile Overall ScoreISPC MarketRank™: iSpecimen scored higher than 7% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion0.7 / 5Analyst RatingSell Consensus RatingiSpecimen has received a consensus rating of Sell. The company's average rating score is 1.00, and is based on no strong buy ratings, no buy ratings, no hold ratings, and 1 sell rating.Amount of Analyst CoverageiSpecimen has only been the subject of 1 research reports in the past 90 days.Read more about iSpecimen's stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of iSpecimen is -0.05, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of iSpecimen is -0.05, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioiSpecimen has a P/B Ratio of 6.05. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about iSpecimen's valuation and earnings. Short Interest4.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted7.91% of the float of iSpecimen has been sold short.Short Interest Ratio / Days to CoveriSpecimen has a short interest ratio ("days to cover") of 0.03, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in iSpecimen has recently decreased by 99.07%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldiSpecimen does not currently pay a dividend.Dividend GrowthiSpecimen does not have a long track record of dividend growth. News and Social Media0.7 / 5News SentimentN/A News SentimentiSpecimen has a news sentiment score of -0.95. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.44 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for iSpecimen this week, compared to 2 articles on an average week.Search InterestOnly 12 people have searched for ISPC on MarketBeat in the last 30 days. This is a decrease of -29% compared to the previous 30 days.MarketBeat FollowsOnly 2 people have added iSpecimen to their MarketBeat watchlist in the last 30 days. This is a decrease of -33% compared to the previous 30 days. Company Ownership0.6 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, iSpecimen insiders have not sold or bought any company stock.Percentage Held by Insiders12.20% of the stock of iSpecimen is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions13.62% of the stock of iSpecimen is held by institutions.Read more about iSpecimen's insider trading history. Receive ISPC Stock News and Ratings via Email Sign-up to receive the latest news and ratings for iSpecimen and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. ISPC Stock News HeadlinesiSpecimen Regains Nasdaq Compliance and Raises New CapitalMay 14, 2026 | theglobeandmail.comE.F. Hutton & Co. Serves as Exclusive Placement Agent on iSpecimen Inc. $2.5 Million Private PlacementMay 12, 2026 | globenewswire.com$30 stock to buy before Starlink goes public (WATCH NOW!)A little-known stock pick with money-doubling potential over the next year is revealed for free in the first three minutes of a new video. This company is a critical piece of Elon Musk's fast-growing Starlink technology. It could climb 100 percent or more over the next year as Elon brings Starlink public in what may be the biggest IPO in history. No credit card is required to get the ticker.May 23 at 1:00 AM | Paradigm Press (Ad)iSpecimen announces pricing of approximately $2.5M private placementMay 11, 2026 | msn.comiSpecimen Inc. Announces Pricing of Approximately $2.5 Million Private PlacementMay 8, 2026 | globenewswire.comiSpecimen Completes 1-for-40 Reverse Stock SplitMay 1, 2026 | tipranks.comiSpecimen IncApril 28, 2026 | edition.cnn.comTop pre-market gainers today — ISPC, WGRX, RAYA among stocks that are soaring before the bellApril 10, 2026 | msn.comSee More Headlines ISPC Stock Analysis - Frequently Asked Questions How have ISPC shares performed this year? iSpecimen's stock was trading at $10.4040 at the beginning of the year. Since then, ISPC stock has decreased by 66.8% and is now trading at $3.45. How were iSpecimen's earnings last quarter? iSpecimen Inc. (NASDAQ:ISPC) issued its earnings results on Friday, May, 15th. The company reported ($6.66) earnings per share (EPS) for the quarter. The business had revenue of $0.16 million for the quarter. iSpecimen had a negative net margin of 1,080.16% and a negative trailing twelve-month return on equity of 584.65%. When did iSpecimen's stock split? iSpecimen shares reverse split before market open on Tuesday, April 28th 2026.A 1-40 reverse split was announced. The number of shares owned by shareholders was adjusted after the closing bell on Monday, April 27th 2026. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split. When did iSpecimen IPO? iSpecimen (ISPC) raised $20 million in an initial public offering (IPO) on Tuesday, June 15th 2021. The company issued 2,250,000 shares at $8.00-$10.00 per share. ThinkEquity (a division of Fordham Financial Management) served as the underwriter for the IPO. How do I buy shares of iSpecimen? Shares of ISPC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of iSpecimen own? Based on aggregate information from My MarketBeat watchlists, some other companies that iSpecimen investors own include NVIDIA (NVDA), Meta Platforms (META), Broadcom (AVGO), Adobe (ADBE), Advanced Micro Devices (AMD), Arista Networks (ANET) and Braze (BRZE). Company Calendar Last Earnings5/15/2026Today5/23/2026Next Earnings (Estimated)8/04/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (4m+) 1-Year History May 25 Aug 25 Nov 25 Feb 26 May 26 ISPC's financial health is in the Red zone, according to TradeSmith. ISPC has been in this zone for over 4 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Medical Services Sub-IndustryBusiness Services Current SymbolNASDAQ:ISPC CIK1558569 Webispecimen.com Phone781-301-6700FaxN/AEmployees60Year FoundedN/AProfitability EPS (Trailing Twelve Months)($72.26) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$10.49 million Net Margins-1,080.16% Pretax Margin-1,080.25% Return on Equity-584.65% Return on Assets-142.48% Debt Debt-to-Equity RatioN/A Current Ratio0.62 Quick Ratio1.12 Sales & Book Value Annual Sales$1.93 million Price / Sales2.57 Cash FlowN/A Price / Cash FlowN/A Book Value$0.57 per share Price / Book6.05Miscellaneous Outstanding Shares1,440,000Free Float1,262,000Market Cap$4.97 million OptionableNot Optionable Beta1.75 Don't wait for the SpaceX IPOThe space race is growing fast, and you don’t have to wait for SpaceX to go public to invest. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.Get This Free Report This page (NASDAQ:ISPC) was last updated on 5/23/2026 by MarketBeat.com Staff. From Our PartnersSpaceX eyes a 1.75 trillion valuation - here's what to knowElon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a...Brownstone Research | Sponsored$30 stock to buy before Starlink goes public (WATCH NOW!)In the next 3 minutes… James Altucher – legendary investor and venture capitalist… And someone who’s kno...Paradigm Press | SponsoredMy feud with Zohran MamdaniEmmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...Stansberry Research | SponsoredYour book attachedBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredSpaceX IPO hides a much bigger storyThe SpaceX IPO could be the biggest in history at $1.75 trillion - but the real story isn't the IPO itself. ...Weiss Ratings | SponsoredSatellite Images Spot Potential $10 Trillion Discovery'Dark Energy': Elon Musk's Next Potential $10 Trillion Move A highly secure site in West Texas now houses a...Altimetry | SponsoredThe AI stocks about to become worthless (and one that isn't)Louis Navellier - who manages $1.1 billion including $358 million in AI stocks - says a new AI computer being ...InvestorPlace | SponsoredSpaceX just filed. The clock is ticking.Reuters reports Elon Musk filed secretly. Barron's says it's being finalized behind closed doors. CNBC just re...The Oxford Club | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding iSpecimen Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share iSpecimen With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
